Skip to main content

datastreet.in

Nuvama sees 37% upside in this healthcare stock. Should you buy?

Park Medi World is set to benefit from India’s hospital bed shortage and growth in Tier II markets. Nuvama initiated coverage with a ‘Buy’ rating and a target price of ₹280, projecting a 37% upside. The company aims to expand bed capacity significantly by FY28.

Source :- mint – markets Read More

Share it :

Leave a Reply

Your email address will not be published. Required fields are marked *